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Consensus recommendations on behalf of the European Commission research projects Perinatal Lipid Metabolism (PeriLip; www.perilip.org) and
Early Nutrition Programming (EARNEST; www.metabolic-programming.org), developed jointly with representatives of the Child Health Foun-
dation (Stiftung Kindergesundheit; www.kindergesundheit.de), the Diabetic Pregnancy Study Group (DPSG; www.medfak.uu.se/dpsg), the Euro-
pean Association of Perinatal Medicine (EAPM; www.europerinatal.com), the European Society for Clinical Nutrition and Metabolism (ESPEN;
www.espen.org), the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, Committee on Nutrition (ESPGHAN;
www.espghan.org), the International Federation of Placenta Associations (IFPA; http://aculeate.hopto.org/IFPA) and the International Society
for the Study of Fatty Acids and Lipids (ISSFAL; email www.issfal.org.uk).
Members of the Perinatal Lipid Intake Working Group
Gioia Alvino, Juliana von Berlepsch, Hans Konrad Biesalski, Tom Clandinin, Hildegard Debertina, Tamás Decsi, Hans Demmelmaira, Gernot Des-
oyebc, Veronika Dietz, Peter Dodds, Pauline Emmett, Fabio Facchinettid, Matthew W. Gillman, Joachim Heinrich, Emilio Herrerab, Irene Hoesli,
William C. Heird, Matthew Hyde, Kirsi Laitinen, John Laws, Elvira Larqué Daza, Iliana Lopez-Soldado, Maria Makrides, Kim Fleischer Michael-
sene, Sjurdur Olsen, Henar Ortega, Guy Putet, Imogen Rogers, Paola Roggero, Lubos Sobotkaf, Hania Szajewskag, Hope Weiler.
(Representing: aChild Health Foundation, bDPSG, cIFPA, dEAPM, eISSFAL, fESPEN, gESPGHAN.)
Dietary fat intake in pregnancy and lactation affects pregnancy outcomes and child growth, development and health. The European Commission
charged the research project PERILIP, jointly with the Early Nutrition Programming Project, to develop recommendations on dietary fat intake in
pregnancy and lactation. Literature reviews were performed and a consensus conference held with international experts in the field, including
representatives of international scientific associations. The adopted conclusions include: dietary fat intake in pregnancy and lactation
(energy%) should be as recommended for the general population; pregnant and lactating women should aim to achieve an average dietary
intake of at least 200 mg DHA/d; intakes of up to 1 g/d DHA or 2·7 g/d n-3 long-chain PUFA have been used in randomized clinical trials without
significant adverse effects; women of childbearing age should aim to consume one to two portions of sea fish per week, including oily fish; intake
of the DHA precursor, a-linolenic acid, is far less effective with regard to DHA deposition in fetal brain than preformed DHA; intake of fish or
other sources of long-chain n-3 fatty acids results in a slightly longer pregnancy duration; dietary inadequacies should be screened for during
pregnancy and individual counselling be offered if needed.
PUFA: DHA: Arachidonic acid: Lipid soluble antioxidants: Vitamin E: Vitamin C
The dietary fat intake of pregnant women affects pregnancy
outcomes, and fat intake during pregnancy and lactation
modulates the growth, development and health of their chil-
dren. In view of the relevance of this issue for public health,
the European Commission charged the European research
project PeriLip (Influence of Dietary Fatty Acids on the Patho-
physiology of Intrauterine Foetal Growth and Neonatal
Development; http://www.imperial.ac.uk/agriculturalsciences/
PeriLip/) in their project contract to develop recommendations
on dietary fat intake in pregnancy and lactation, based on
current scientific evidence and any new findings from the Peri-
Lip project. The PeriLip Steering Committee and the Project
Coordinating Committee of the Early Nutrition Programming
project (EARNEST, www.metabolic-programming.org)
agreed to jointly perform this task, to approach it by a
review of the available scientific evidence and by a consensus
workshop with leading international experts in the area. Issues
to be addressed included advisable intakes of dietary fat, fatty
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acids and antioxidants during normal pregnancies and
lactation. This report describes the conclusions drawn and
recommendations made.
Methods
Berthold Koletzko and Irene Cetin were asked to coordinate
the project and asked J. Thomas Brenna to join the coordi-
nation committee. Based on an initial search and review of
the available scientific literature, critical topics were chosen
and collaborators identified to perform the detailed literature
reviews. The effects of n-3 PUFA intakes for women with
low-risk pregnancies and with high-risk pregnancies were
reviewed by Andrea Horvath, Berthold Koletzko and Hania
Szajewska. Maternal PUFA intake during lactation and its
effects on human milk composition and infantile outcome
were reviewed by Hans Demmelmair and Berthold Koletzko.
The effects of antioxidant intakes in pregnant and lactating
women were reviewed by Hans Konrad Biesalski. Recent
reviews of toxicological evaluations on sea fish consumption
in women of childbearing age by the European Food Safety
Authority as well as a Cochrane review on the effects of n-3
PUFA intakes and of antioxidants for pregnant women were
also evaluated.
These reviews, further background information and perti-
nent publications were shared through a dedicated website
with the participants of an expert workshop held from
11–14 September 2005 at Wildbad Kreuth, Bavaria,
Germany. The invited participants were project partners of
the PeriLip and EARNEST research projects with expertise
in the field, experts nominated by scientific societies related
to the area and experts in science, nutrition, clinical medicine
and public health nominated by project partners. The work-
shop participants reviewed and discussed the systematic litera-
ture reviews mentioned earlier and other data presented at the
workshop and they unanimously agreed on the conclusions
presented herein.
Results of the evaluation
Total dietary fat intake
Pregnancy leads to a modest increase of energy needs in the
order of 375, 1200, 1950 kJ per d for the first, second and
third trimesters of pregnancy, respectively1,2. Well-nourished
lactating women have a net increase of energy needs of the
order of 1900 kJ per d above the energy requirements of non-
pregnant, non-lactating women. These added energy needs
can normally be met by a modest increase in consumption
of a balanced diet. There is no indication that recommen-
dations for dietary total fat intake, expressed as a percentage
of energy intake, need to differ in pregnancy and lactation
from those for non-pregnant, non-lactating women.
Dietary fatty acid intake
No evidence was identified to demonstrate a need for changing
the dietary fatty acid composition of pregnant or lactating
women, with regard to the intake of saturated, trans-isomeric,
MUFA and PUFA relative to recommended intakes for the
general population, except for the intake of n-3 long-chain
PUFA (LC-PUFA).
The n-3 LC-PUFA, DHA, must be deposited in appreciable
amounts in the central nervous system during the perinatal
brain growth spurt, as well as in other membrane-rich
tissues. Fetal DHA accretion amounts to about
30–45 mg per d in the last trimester of gestation, while arachi-
donic acid accretion mainly occurs postnatally 3,4. The path-
ways to form DHA from the precursor essential fatty acid,
a-linolenic acid, exist in man. The fractional conversion of
a-linolenic acid to n-3 LC-PUFA may be greater in women
than in men, which may contribute to meeting the demands
of the fetus and the breast-fed neonate for DHA, but most evi-
dence indicates that the overall contribution of a-linolenic
acid to DHA is limited; therefore, adequate intakes of
preformed n-3 LC-PUFA, and in particular DHA, appear
important for maintaining optimal tissue function 5 – 7. In
intrauterine growth-restricted pregnancies, indications for
reduced placental and/or fetal conversion of precursor essen-
tial fatty acids to LC-PUFA have been reported8. Moreover,
recent data indicate a considerable inter-individual variation
in the ability to convert the precursor a-linolenic acid to n-3
LC-PUFA, related to common polymorphisms in the human
D-5 and D-6 desaturase genes FADS1 and FADS29. Pre-
formed DHA is preferentially transferred across the human
placenta to the fetus mediated by specific transfer pro-
teins10,11. In non-human primates, preformed dietary DHA is
about an order of magnitude more efficient as a source for
the neonatal brain accretion of DHA than is a-linolenic acid12.
The effects of supplementing pregnant women with n-3 LC-
PUFA from fish oil or single cell oils on pregnancy outcomes
have been evaluated in a number of randomized controlled
clinical trials, which provided daily DHA intakes ranging
from 150–200 mg up to about 1200 mg/d, or up to 2·7 g
total n-3 LC-PUFA/d. Systematic evaluation of these studies
in recent meta analyses revealed that n-3 LC-PUFA prolonged
gestation by a mean of 1·6 or 2·6 d in two independent ana-
lyses, respectively13,14, accompanied by a slight increase of
birth weight by a mean 47 or 54 g, respectively13,14 and
reduced the risk of preterm birth before 34 weeks of gestation
by 31 % in all pregnancies14 or by 61 % in high-risk pregnan-
cies15. Except for some reported discomfort associated with
the intake of n-3 oil capsules, such as belching and unpleasant
taste, no adverse effects were detected up to the highest intake
of 2·7 g total n-3 LC-PUFA/d tested in a randomized con-
trolled trial in pregnancy.
Enhanced maternal dietary intakes of DHA increase fetal
supply and lead to higher DHA concentrations in cord
blood16. A higher DHA supply to the fetus during pregnancy
and to the infant after birth was associated with beneficial
effects on the development of visual acuity, cognitive func-
tions and attention, maturity of sleep patterns, spontaneous
motor activity, immune phenotypes in cohort studies and in
a limited number of randomized clinical trials17 – 28. Further
randomized trials with large sample sizes of pregnant
women are currently in progress, which should provide more
information on the extent of benefits. Based on the infor-
mation available at this time, it is advisable that pregnant
women aim at achieving an average intake of at least
200 mg DHA/d. Supplementation of lactating women with
200 mg DHA/d increased human milk DHA content by
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about 0·2 % fatty acids to a level considered desirable for
infant outcomes29,30. Therefore, an average dietary intake of
at least 200 mg DHA/d appears to be also adequate during
lactation.
The desired average intake of at least 200 mg DHA/d can be
reached with the consumption of one to two portions of sea
fish per week, including oily fish such as herring, mackerel
and salmon. Since fish can contribute significantly to the diet-
ary exposure of contaminants such as methylmercury, dioxins
and polychlorinated biphenyls, brominated flame retardants,
camphechlor and organotin, the safety of fish consumption
with particular regard to the vulnerable groups of pregnant
and lactating women and their children has been
reviewed31,32. Levels of bioaccumulative contaminants tend
to be greater in large fish that are higher in the food chain.
Individuals consuming high levels of particular fish may
exceed the provisional tolerable weekly intake, even without
taking into account other sources of dietary exposure.
The greatest susceptibility to the critical contaminants
methylmercury and the dioxin-like compounds occurs
during early development. Methylmercury is particularly
toxic to the developing brain and may also adversely
affect child growth20,33,34. A woman can decrease the
amounts of methylmercury in her body by reducing the
intake of contaminated foods in the months prior to and
during pregnancy. The fish with the highest methylmercury
contents are predator fish such as marlin, pike, swordfish
and shark; hence, women of childbearing age should not
give undue preference to consumption of these fish species.
In contrast, food choice during pregnancy has little effect on
fetal exposure of dioxin-like compounds and polychlorinated
biphenyls, because avoidance of contaminated foods would
take many years to markedly decrease the amounts stored
in the body. The fish with the highest levels of dioxin-like
compounds and polychlorinated biphenyls are herring,
which are caught from the wild, and salmon, which are
mostly farmed. The European Food Safety Authority con-
cluded that pregnant women eating up to two portions per
week of fish are unlikely to exceed the provisional tolerable
weekly intake for dioxin and dioxin-like compounds. How-
ever, particularly high levels of contamination are found in
herring or wild salmon from the Baltic Sea and women of
childbearing age should limit the consumption of Baltic
Sea herring or wild salmon to no more than one portion
per week.
Since cohort studies both in Europe and in the USA
reported positive associations of higher fish intake by pregnant
women with higher infant cognition, verbal intelligence quoti-
ent, pro-social behaviour, fine motor, communication and
social development scores20,35, the beneficial effects of regular
fish consumption providing n-3 LC-PUFA during pregnancy
appear to outweigh potential disadvantages from increased
intakes of contaminants.
Plasma and tissue contents of the n-6 LC-PUFA arachidonic
acid are relatively stable, even if pregnant women are sup-
plemented with DHA-rich oils16,36. Tissue arachidonic acid
does not appear to be influenced by the dietary intake of
preformed arachidonic acid as much as DHA. There are no
indications that women of childbearing age with an adequate
dietary intake of the precursor fatty acid linoleic acid would
need an additional dietary supply of arachidonic acid.
Antioxidants
Oxidative stress has been implicated in many pathological pro-
cesses during pregnancy, child birth and the postnatal period,
but the possible preventive or therapeutic effects of antioxi-
dants remain controversial37,38. Recent systematic reviews on
the effects from supplementation of antioxidant vitamins in
pregnancy did not reveal conclusive evidence of benefits of
intakes above reference nutrient intakes39,40 – 43. A review of
all randomized and quasi-randomized trials performed prior
to 2005 on the effects of one or more antioxidants during
pregnancy for the prevention of pre-eclampsia, which
included seven trials involving 6082 women, found that supple-
menting women with any antioxidants during pregnancy,
compared with control or placebo, was associated with a
39 % reduction in the risk of pre-eclampsia and a 35 % risk
reduction of having a small-for-gestational-age infant44.
Infants of women receiving antioxidants also had a greater
mean birth weight (weighted mean difference 92 g), but
they were more likely to be born preterm (relative risk
1·38). However, the authors of the review point out that
these data should be interpreted with caution because most
of the data come from poor quality studies. Two further,
large randomized controlled trials, with supplementation of
high dosages of both vitamins C and E, did not show any
reduction in the incidence of pre-eclampsia, but in one of
the two trials vitamin C and E supplementation was associ-
ated with a significantly higher rate of low birth weight
infants45,46. Overall, the currently available data do not
provide a basis for recommending antioxidant intakes for
pregnant and lactating women in excess of reference nutrient
intakes.
Conclusions and recommendations
1. Dietary fat intake during pregnancy and lactation, as a
proportion of energy intake, should be the same as that
recommended for the general population.
2. The n-3 LC-PUFA, DHA, must be deposited in ade-
quate amounts in brain and other tissues during fetal
and early postnatal life. Several studies have shown
an association between maternal dietary intake of oily
fish or oils providing n-3 LC-PUFA during pregnancy
and/or lactation and visual and cognitive development
as well as other functional outcomes of the infants.
Pregnant and lactating women should aim to achieve
a dietary intake of n-3 LC-PUFA that supplies a
DHA intake of at least 200 mg/d. Intakes of up to
1 g/d DHA or 2·7 g/d n-3 LC-PUFA have been used
in randomized trials without occurrence of significant
adverse effects.
3. Women of childbearing age can meet the recommended
intake of DHA by consuming one to two portions of
sea fish per week, including oily fish, which is a good
source of n-3 LC-PUFA. This intake of oily fish rarely
exceeds the tolerable intake of environmental contami-
nants. Dietary fish should be selected from a wide
range of species without undue preference for large pre-
datory fish, which are more likely to be contaminated
with methylmercury.
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4. Intake of the precursor, a-linolenic acid, is far less effec-
tive with regard to DHA deposition in fetal brain than the
intake of preformed DHA.
5. There is no evidence that women of childbearing age
whose dietary intake of linoleic acid is adequate need
an additional dietary intake of arachidonic acid.
6. Some studies have shown that maternal intake of fish, fish
oils or n-3 LC-PUFA results in a slightly longer duration
of gestation, a somewhat higher birth weight and a
reduced risk of early preterm delivery. The clinical
importance of such effects with regard to infant health
has not been fully elucidated.
7. Screening for dietary inadequacies should be performed
during pregnancy, preferably during the first trimester.
If less than desirable dietary habits are detected,
individual counselling should be offered during preg-
nancy as well as during lactation.
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